Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Pinpoint root causes, such as leakage or overspending, then implement targeted adjustments to regain monthly balance.
24,154 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
SpaceX is rapidly expanding into AI-driven solutions beyond rockets. This piece breaks down what a bold forecast from...
XRP remains around the $1 mark as the CLARITY Act stalls in the Senate, raising questions about regulatory clarity an...
Investors are weighing whether lululemon stocks stage turnaround is still on the table. This guide breaks down the fa...
A coalition-backed stablecoin launches as a potential disruptor to USDC. This shift could reshape how institutions ea...
Bitcoin faces renewed pressure around the $60,000 zone with on-chain data suggesting more coins moving to exchanges. ...
When you weigh broad health exposure against a focused pharmaceutical bet, two ETFs stand out: IYH and PJP. This guid...
Apple unveils rebuilt Siri at WWDC, sending shares on a brisk intraday swing as investors parse the AI strategy. The ...
Bitcoin hovers around $74,000 as Pi Network’s PI jumps amid a revival in risk appetite. The move highlights growing r...
Artificial intelligence is delivering measurable efficiency in health care, but the race now focuses on who benefits—...
Joby Aviation has moved lower after hitting a peak. This guide weighs the risks and potential catalysts, and offers a...
A deadly cattle parasite remains largely uncontained as a key sterile-fly facility won’t be online until late 2027, r...